Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $64.37M
• Dividend Yield: N/A
• Average Volume (3M): 76.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: -2.08%
• EPS Growth: 40.07%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 66
• Industry: Medical - Devices
• EPS (TTM): -0.38
• Shares Outstanding: 62,500,000
• 10 Day Avg. Volume: 81,118
• 30 Day Avg. Volume: 76,123
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.42
• Price to Cash Flow (P/CF): -5.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: -2.91% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Cytosorbents faces significant financial challenges, with declining revenues, high leverage, and negative cash flows. Despite positive revenue growth and liquidity improvements noted in recent earnings and corporate events, technical and valuation concerns persist. Financial performance remains the primary concern, impacting the overall stock score.

Positive Factors

Product Launch

The launch of PuriFi, a novel hemoperfusion pump, continues to go well with many evaluations ongoing.

Product Revenue Growth

Product revenues increased by 25% year-over-year and 6% quarter-over-quarter, driven by a 28% increase in direct sales outside of Germany and a 22% increase in global distributor sales.

Regulatory Approval

The regulatory approval of DrugSorb-ATR in the U.S. and Canada could make it the first device indicated for the removal of antithrombotic agents during cardiac surgery in these markets.

Negative Factors

Commercial Reorganization

Short-term disruptions could impact topline revenues in the first quarter of 2025 due to the commercial reorganization in Germany.

Financial Performance

The company reported revenues and net loss that were below consensus estimates, with $9.2M in product revenues and a net loss of $0.14 per share.

Gross Margin Decline

The company's blended product gross margin for the quarter decreased to 61%, compared to 72% in 3Q23 and 75% in 2Q24.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation (CTSO) is a medical device company specializing in blood purification technologies to treat life-threatening conditions in the intensive care unit and cardiac surgery. The company's flagship product, CytoSorb, is an extracorporeal cytokine adsorber designed to reduce cytokine storm and other toxins in critically ill patients. Cytosorbents operates primarily in the healthcare sector, focusing on critical care and cardiac surgery markets.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its CytoSorb device, which is marketed and sold to hospitals and healthcare facilities worldwide. The company also engages in strategic partnerships and collaborations with other healthcare organizations to expand the adoption of its technology. Key revenue streams include direct sales of CytoSorb, licensing agreements, and government or institutional grants for research and development. Additionally, the company may earn income from clinical trial support and related consultancy services.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents faces significant financial challenges, with consistent losses and negative cash flows impacting its financial health. While revenue growth in the TTM period offers some optimism, the company struggles with high leverage and operational inefficiencies. Improving profitability and cash flow generation are crucial for long-term sustainability.

Income Statement

Cytosorbents' revenue has shown significant volatility, with a sharp increase in TTM (Trailing-Twelve-Months) revenue, indicating potential growth opportunities. However, the company continues to operate at a loss, as reflected in negative EBIT and net income, which has worsened over time. The negative EBIT and EBITDA margins suggest operational inefficiencies or high fixed costs. Despite the revenue growth, persistent losses and negative profit margins highlight challenges in achieving profitability.

Balance Sheet

The balance sheet reflects high leverage with a consistent increase in total liabilities over the years. The company has a low equity base, which is concerning for financial stability. The debt-to-equity ratio is high, indicating potential financial risk. However, the company has maintained adequate cash reserves, which provide some liquidity cushion. The return on equity remains negative due to consistent losses, impacting shareholder value.

Cash Flow

Cytosorbents shows negative operating cash flow, indicating challenges in generating cash from its core operations. The free cash flow remains negative, and the free cash flow growth rate is also concerning. Despite financing inflows, the operating cash flow to net income ratio suggests inefficiency in converting net income into cash. The cash flow situation highlights a need for better cash management or operational improvements.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
36.96M	36.35M	29.36M	40.11M	39.45M	22.77M
	Gross Profit
22.89M	22.39M	15.40M	29.06M	28.40M	15.40M
	EBIT
-21.65M	-31.21M	-31.52M	-22.75M	-10.37M	-18.97M
	EBITDA
-19.80M	-29.18M	-30.00M	-22.01M	-9.71M	-18.74M
	Net Income Common Stockholders
-18.67M	-28.51M	-32.81M	-24.56M	-7.84M	-19.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.35M	14.13M	22.14M	52.14M	71.42M	12.23M
	Total Assets
1.69M	53.26M	63.23M	89.52M	89.95M	27.38M
	Total Debt
172.50K	18.31M	18.25M	13.82M	1.03M	16.12M
	Net Debt
-1.17M	4.18M	-3.89M	-38.32M	-70.39M	3.89M
	Total Liabilities
1.32M	29.99M	27.86M	26.94M	10.73M	23.96M
	Stockholders Equity
367.36K	23.28M	35.38M	62.58M	79.22M	3.42M
Cash Flow		Free Cash Flow
-19.17M	-22.59M	-34.69M	-18.29M	-7.29M	-18.28M
	Operating Cash Flow
-18.49M	-21.66M	-28.23M	-14.01M	-5.61M	-16.76M
	Investing Cash Flow
-681.16K	-936.24K	-6.46M	-4.28M	-1.68M	-1.52M
	Financing Cash Flow
21.37M	14.47M	4.96M	715.20K	66.35M	8.18M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.03
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.06, and below the 200-day MA of 1.04, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FMS	72 Outperform	$13.87B	23.85	3.87%	1.87%	-0.57%	8.25%
TMO	71 Outperform	$169.62B	27.17	13.15%	0.37%	0.05%	6.87%
MMM	64 Neutral	$70.22B	17.24	97.86%	2.17%	-18.72%	―
DVA	64 Neutral	$11.20B	13.03	159.08%	―	5.56%	45.02%
Sector *	51 Neutral	$5.19B	3.13	-40.94%	2.95%	17.94%	2.00%
BAX	47 Neutral	$14.82B	136.07	-9.24%	3.18%	-14.00%	-184.82%
CTSO	45 Neutral	$64.37M	―	-120.52%	―	-2.08%	40.07%

Cytosorbents Corporate Events

CytoSorbents Appoints New VP and Corporate Controller

On April 17, 2025, CytoSorbents Corporation announced the appointment of Melanie Grossman as Vice President and Corporate Controller, effective April 14, 2025. Grossman, who brings over 25 years of finance and accounting experience, will receive stock awards as an inducement grant under Nasdaq Rule 5635(c)(4). Her expertise is expected to support CytoSorbents’ growth and the potential launch of DrugSorb™-ATR in North America, enhancing the company’s operational efficiency and market positioning.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ stock faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. While recent earnings and corporate events show positive trends in revenue growth and liquidity, these are offset by technical and valuation concerns, leading to a cautious overall score.

To see Spark’s full report on CTSO stock, click here.

Cytosorbents Appoints New VP of Marketing

On April 14, 2025, CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America. Shannon, with over 25 years of experience in commercializing cardiovascular and critical care technologies, will lead the marketing strategy for DrugSorb™-ATR in the U.S. and Canada. This appointment comes as the company prepares for the potential launch of DrugSorb-ATR, a device aimed at reducing perioperative bleeding in patients undergoing coronary artery bypass graft surgery while on blood thinners. The device is currently under review by the U.S. FDA and Health Canada, with regulatory decisions expected in 2025.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ stock faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. While recent earnings and corporate events show positive trends in revenue growth and liquidity, these are offset by technical and valuation concerns, leading to a cautious overall score.

To see Spark’s full report on CTSO stock, click here.

CytoSorbents Reschedules Earnings Release to March 2025

CytoSorbents Corporation announced the rescheduling of its fourth quarter and full year 2024 earnings release to March 31, 2025, to allow additional time for the completion of its annual audit. The company reaffirmed its preliminary financial results, expecting significant growth in product revenue and gross margin compared to the previous year. The company’s marketing applications for DrugSorb-ATR are under review by the U.S. FDA and Health Canada, with decisions anticipated in 2025. Additionally, CytoSorbents raised $7.85 million in the first quarter of 2025, enhancing its cash position as it continues to develop its innovative blood purification technologies.

CytoSorbents Delays Earnings Release to March 25, 2025

CytoSorbents Corporation announced the postponement of its earnings release, originally scheduled for March 6, 2025, to March 25, 2025, following the passing of its Vice President and Corporate Controller, James E. Cason, Jr. The company reaffirmed its preliminary financial results for 2024, expecting significant growth in product revenue and gross margins. The delay aims to ensure a thorough completion of the annual audit. CytoSorbents also continues to anticipate regulatory decisions on its DrugSorb™-ATR marketing applications in 2025, which are under review by the U.S. FDA and Health Canada.

CytoSorbents Boosts Liquidity with Warrant Expiration

On February 25, 2025, CytoSorbents Corporation announced the expiration of its Series A Right Warrants, resulting in $1.6 million in gross proceeds from their exercise. This event, combined with previous fundraising efforts, has strengthened the company’s balance sheet by increasing net liquidity to approximately $12.3 million. The proceeds are intended to support innovation and expansion in CytoSorbents’ core international business and aid in the potential U.S. and Canadian approval of their DrugSorb™-ATR product in 2025. The company also highlighted the ongoing progress of their regulatory applications with the U.S. FDA and Health Canada, expecting decisions in 2025.